{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"title":"Grade 4 pericardial effusion"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"Grade 5 pneumonitis"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"Here are the grade ≥3 adverse events at each dose level assessed by the Common Terminology Criteria in Adverse Events CTCAE v5.0. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 3 is Severe or medically significant but not immediately life-threatening;hospitalization or prolongation of hospitalization indicated; disabling;limiting self care ADL (i.e., bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden. Grade 4 is life-threatening consequences;urgent intervention indicated. Grade 5 is death related to adverse event.","groups":[{"description":"Dose escalation - patients with mesothelioma treated with LMB-100+SEL-110 at escalating doses\n\nLMB-100: administered on days 1, 3 and 5 of each 21 day cycle for up to 4 cycles\n\nSEL-110: administered on day 1 of each cycle for up to 4 cycles","id":"OG000","title":"140 mcg/kg"},{"description":"Dose escalation - patients with mesothelioma treated with LMB-100+SEL-110 at escalating doses\n\nLMB-100: administered on days 1, 3 and 5 of each 21 day cycle for up to 4 cycles\n\nSEL-110: administered on day 1 of each cycle for up to 4 cycles","id":"OG001","title":"100 mcg/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Day 85","title":"Number of Participants With Grade ≥3 Adverse Events Related to Study Drug at Dose Level 140 mcg/kg and 100 mcg/kg","type":"PRIMARY","unitOfMeasure":"Participants"}